I agree that this site is using cookies. You can find further informations here.
X
Pérol, M.
~ 300  results:
Search for persons X
?
1

26P Prognostic factors and outcomes of patients (Pts) with ..:

Pérol, M. ; Chouaid, C. ; Bjerrum, A....
ESMO Open.  9 (2024)  - p. 102605 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Clinical characteristic and survival outcomes of patients w..:

Thomas, Q.D. ; Quantin, X. ; Lemercier, P....
ESMO Open.  9 (2024)  6 - p. 103473 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Antibody–drug conjugates in lung and breast cancer: current..:

Peters, S. ; Loi, S. ; André, F....
Annals of Oncology.  35 (2024)  7 - p. 607-629 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Treatment sequences in EGFR mutant advanced NSCLC:

Wespiser, M. ; Swalduz, A. ; Pérol, M.
Lung Cancer.  , 2024
Link: https://doi.org/10.1016/..
 
?
5

59P Datopotamab deruxtecan (Dato-DXd) in patients with prev..:

Girard, N. ; Okamoto, I. ; Lisberg, A.E....
ESMO Open.  9 (2024)  - p. 102638 , 2024
Link: https://doi.org/10.1016/..
 
?
6

P2.10-15 Correlation Between Clinical and Health-related Qu..:

García-Campelo, R. ; Lin, H.M. ; Pérol, M....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S358-S359 , 2023
Link: https://doi.org/10.1016/..
 
?
7

76P Immune checkpoint inhibitor (ICI) retreatment patterns ..:

Justeau, G. ; Pérol, M. ; Valette, C. Audigier...
Immuno-Oncology and Technology.  20 (2023)  - p. 100548 , 2023
Link: https://doi.org/10.1016/..
 
?
8

78P Final analysis of the French real-world study EVIDENS: ..:

Barlesi, F. ; Dixmier, A. ; Debieuvre, D....
Immuno-Oncology and Technology.  20 (2023)  - p. 100550 , 2023
Link: https://doi.org/10.1016/..
 
?
9

MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant..:

Janne, P. ; Goto, Y. ; Kubo, T....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S148 , 2023
Link: https://doi.org/10.1016/..
 
?
10

202P The therapeutic cancer vaccine PDC*lung01 induces immu..:

Sibille, A. ; Plumas, J. ; Demedts, I....
Immuno-Oncology and Technology.  16 (2022)  - p. 100313 , 2022
Link: https://doi.org/10.1016/..
 
?
11

The value of disease-free survival (DFS) and osimertinib in..:

Hardenberg, M.C. ; Patel, B. ; Matthews, C....
ESMO Open.  7 (2022)  5 - p. 100572 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Real-world overview of therapeutic strategies and prognosis..:

Cabart, M. ; Mourey, L. ; Girard, N....
Journal of Geriatric Oncology.  12 (2021)  8 - p. S3 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Corrigendum to 'First-line nivolumab plus ipilimumab with 2..:

Reck, M. ; Ciuleanu, T.-E. ; Cobo, M....
ESMO Open.  6 (2021)  6 - p. 100345 , 2021
Link: https://doi.org/10.1016/..
 
?
14

First-line nivolumab plus ipilimumab with two cycles of che..:

Reck, M. ; Ciuleanu, T.-E. ; Cobo, M....
ESMO Open.  6 (2021)  5 - p. 100273 , 2021
Link: https://doi.org/10.1016/..
 
?
15

Immune checkpoint inhibitor treatment of a first cancer is ..:

Heudel, P. ; Chabaud, S. ; Perol, D....
ESMO Open.  6 (2021)  1 - p. 100044 , 2021
Link: https://doi.org/10.1016/..
 
1-15